Jenburkt Pharmaceuticals Ltd
Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 06 Aug 2026, 08:05 PM IST · BSE ID: 14c58c0f-6a90-4709-a27a-e04560672a71
View Original BSE Filing (PDF)
💡
In Simple Terms
Jenburkt Pharmaceuticals' profit for the first quarter of FY27 decreased by 24.47% compared to the same period last year.
🤖 AI Summary
- Net Profit After Tax for Q1 FY27 stood at Rs. 588.56 Lacs, down 24.47% from Rs. 779.18 Lacs YoY.
- Revenue from Operations for the quarter ended June 30, 2026, was Rs. 3551.20 Lacs.
- Total Income for Q1 FY27 was Rs. 3702.52 Lacs, a 1.49% decrease compared to Rs. 3758.39 Lacs in Q1 FY26.
- Total Expenses increased to Rs. 3025.61 Lacs in Q1 FY27 from Rs. 2740.19 Lacs in the corresponding prior period.
- Basic and Diluted Earnings Per Share for the quarter ended June 30, 2026, was Rs. 13.34.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
3551.20 Lacs
-0.04
Total Income
3702.52 Lacs
-1.49
Total Expenses
3025.61 Lacs
10.42
Profit before tax
676.91 Lacs
-33.51
Profit/(Loss) after Tax
588.56 Lacs
-24.47
Earnings Per Share (Basic and Diluted)
13.34 Rs.
-24.46
🏢 How This Affects the Company
The marginal decline in revenue from operations suggests stable business activity compared to the prior year, but growth was not observed.
The significant decrease in net profit and total income indicates pressure on profitability, impacting overall earnings for the quarter.
Total expenses rose to Rs. 3025.61 Lacs from Rs. 2740.19 Lacs, driven by increases in employee benefit expenses and other expenses, signaling higher operational costs.
👥 What This Means For Shareholders
✅
Action Required
No action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as Q1 FY27 Net Profit After Tax declined to Rs. 588.56 Lacs.
🔍
Management Signal
The Board approved the unaudited financial results, indicating a formal acknowledgement of the current financial performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for revenue and profit trends.
Analysis of cost structure — identify drivers behind increased expenses.
Management commentary on business outlook and market conditions.
MEDIUM RISK
Significant year-on-year decline in net profit while revenue remains flat indicates pressure on profitability.
💡 Investor Takeaway
Jenburkt Pharmaceuticals reported Q1 FY27 net profit after tax of Rs. 588.56 Lacs, a 24.47% decrease year-on-year from Rs. 779.18 Lacs. Revenue from operations remained largely stable at Rs. 3551.20 Lacs compared to Rs. 3552.68 Lacs in Q1 FY26, with higher total expenses observed.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from Operations for Q1 FY27 was Rs. 3551.20 Lacs, maintaining a level similar to Rs. 3552.68 Lacs in Q1 FY26.
- Cost of Materials Consumed increased to Rs. 231.59 Lacs in Q1 FY27 from Rs. 213.54 Lacs in Q1 FY26, indicating sustained input usage.
⚠️ Concerns
- Net Profit After Tax declined by 24.47% to Rs. 588.56 Lacs in Q1 FY27 from Rs. 779.18 Lacs in Q1 FY26.
- Profit before tax decreased by 33.51% to Rs. 676.91 Lacs in Q1 FY27 from Rs. 1018.20 Lacs in Q1 FY26.
📅 Company Track Record
Jenburkt Pharmaceuticals' Q1 FY27 net profit declined by 24.47% year-on-year. This follows a previous announcement on August 6, 2026, confirming a net profit decline of 24.47% for Q1 FY27. The company's Q4 FY26 results were due for board approval on May 5, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Jenburkt Pharmaceuticals' net profit for Q1 FY27?
Jenburkt Pharmaceuticals reported a standalone net profit after tax of Rs. 588.56 Lacs for the quarter ended June 30, 2026.
How did Jenburkt Pharmaceuticals' revenue from operations perform in Q1 FY27?
Revenue from operations for Jenburkt Pharmaceuticals in Q1 FY27 was Rs. 3551.20 Lacs, a marginal decrease from Rs. 3552.68 Lacs in Q1 FY26.
What was the year-on-year change in net profit for Jenburkt Pharmaceuticals in Q1 FY27?
Jenburkt Pharmaceuticals' net profit after tax for Q1 FY27 decreased by 24.47% to Rs. 588.56 Lacs compared to Rs. 779.18 Lacs in Q1 FY26.
What were the total expenses for Jenburkt Pharmaceuticals in Q1 FY27?
Total expenses for Jenburkt Pharmaceuticals in Q1 FY27 amounted to Rs. 3025.61 Lacs, up from Rs. 2740.19 Lacs in Q1 FY26.
What was the Earnings Per Share (EPS) for Jenburkt Pharmaceuticals in Q1 FY27?
The Basic and Diluted Earnings Per Share for Jenburkt Pharmaceuticals in Q1 FY27 was Rs. 13.34.
Questions based on this BSE filing only. For information purposes.